Israel Bans Key Immunoglobulin Drug, Creating National Shortage
This article was originally published in PharmAsia News
Israelis face a massive shortage of a key drug in the aftermath of the withdrawal of Omrigam, an immunoglobulin drug developed from blood plasma
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.